Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey

References

• 1. Friedman DZP, Schwartz IS. Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens. J Fungi (Basel). 2019;5(3):67.
   Google Scholar
• 2. Goemaere B, Becker P, Van Wijngaerden E, Maertens J, Spriet I, Hendrickx M, et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018;61(2):127–33.
   PubMed Web of Science ®Google Scholar
• 3. Khan Z, Ahmad S, Al-Sweih N, Mokaddas E, Al-Banwan K, Alfouzan W, et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS One. 2019;14(5):e0216250
   PubMed Web of Science ®Google Scholar
• 4. Mirhendi H, Charsizadeh A, Eshaghi H, Nikmanesh B, Arendrup MC. Species distribution and antifungal susceptibility profile of Candida isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran. Med Mycol. 2019;58(2):201–206.
   Web of Science ®Google Scholar
• 5. Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect. 2014;20(Suppl 6):42–8.
   PubMedGoogle Scholar
• 6. Fraser M, Borman AM, Thorn R, Lawrance LM. Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida Glabrata: Fifteen years of interpretation and assessment. Med Mycol. 2019;58(2):219–226.
   Web of Science ®Google Scholar
• 7. Lindberg E, Hammarström H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci Rep. 2019;9(1):3838
   PubMedGoogle Scholar
• CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed. CLSI Supplement M60. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• 9. EUCAST Definitive Document E.DEF 7.3.2 Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. April, 2020. https://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/.
   Google Scholar
• 10. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13(6):180–95.
   PubMed Web of Science ®Google Scholar
• 11. Koehling HL, Willinger B, Buer J, Rath PM, Steinmann J. Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates. J Clin Microbiol. 2015;53(1):255–61.
   PubMed Web of Science ®Google Scholar
• 12. Sanguinetti M, Posteraro B. Susceptibility Testing of Fungi to Antifungal Drugs. J Fungi (Basel). 2018;4(3):110.
   Google Scholar
• 13. Posteraro B, Spanu T, Fiori B, De Maio F, De Carolis E, Giaquinto A, et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother. 2015;59(7):3944–55.
   PubMed Web of Science ®Google Scholar
• 14. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.
   PubMed Web of Science ®Google Scholar
• 15. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409– 50.
   PubMedGoogle Scholar
• 16. Arendrup MC, Patterson TF. Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. J Infect Dis. 2017;216(suppl_3):S445–S451.
   PubMedGoogle Scholar
• 17. Xiao Z, Wang Q, Zhu F, An Y. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China. Antimicrob Resist Infect Control. 2019;8:89.
   PubMed Web of Science ®Google Scholar
• 18. Prigitano A, Cavanna C, Passera M, Gelmi M, Sala E, Ossi C et al. Evolution of fungemia in an Italian region. J Mycol Med. 2020;30(1):100906. Apr
   PubMed Web of Science ®Google Scholar
• 19. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532–8.
   PubMed Web of Science ®Google Scholar
• 20. Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One. 2015;10(5):e0127534.
   PubMed Web of Science ®Google Scholar
• 21. De Rosa FG, Corcione S, Filippini C, Raviolo S, Fossati L, Montrucchio C, et al. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. PLoS One. 2015;10(5):e0125149
   PubMed Web of Science ®Google Scholar
• 22. Luzzati R, Merelli M, Ansaldi F, Rosin C, Azzini A, Cavinato S, et al. Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. Infection. 2016;44(6):747–55.
   PubMed Web of Science ®Google Scholar
• 23. Vena A, Bouza E, Valerio M, Padilla B, Paño-Pardo JR, Fernández-Ruiz M, et al. Candidemia in non-ICU surgical wards: Comparison with medical wards. PLoS One. 2017;12(10):e0185339.
   PubMed Web of Science ®Google Scholar
• 24. Pinto-Magalhães S, Martins A, Lacerda S, Filipe R, Prista-Leão B, Pinheiro D, et al. Candidemia in a Portuguese tertiary care hospital: Analysis of a 2-year period. J Mycol Med. 2019;29(4):320–324pii. S1156-5233(19)30115-5.
   PubMed Web of Science ®Google Scholar
• 25. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age?. Clin Infect Dis. 2002;35(8):982–9.
   PubMed Web of Science ®Google Scholar
• 26. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72(4):1103–8.
   PubMed Web of Science ®Google Scholar